GLP-1 Feud Ends: NOVO, HIMS Join Forces (Again) To Sell Obesity Drugs

Core Viewpoint - The long-standing dispute between Novo Nordisk and Hims & Hers Health is reportedly coming to an end, with both companies set to announce a new partnership allowing Novo to sell its weight-loss drug Wegovy through Hims' platform [1][2]. Group 1: Partnership Details - Novo Nordisk plans to sell its weight-loss drugs on Hims & Hers Health's platform, marking a significant shift in their relationship [2]. - The two companies had a previous agreement that was terminated by Novo after Hims continued to market copycat medications [2]. Group 2: Market Reaction - Following the news of the partnership, Novo's ADRs rose by 2% in after-hours trading, while Hims' shares surged nearly 40% [4]. - The end of the feud is viewed positively for Hims' stock, as noted by Leerink Partners analyst Michael Cherny [3]. Group 3: Strategic Rationale - Novo's decision to partner with Hims again is likely driven by the need to expand market reach and improve performance amid a competitive obesity treatment landscape [6][9]. - The new CEO of Novo is under pressure from investors to reverse a multi-year stock decline, which may have influenced the decision to collaborate with Hims [9]. Group 4: Analyst Insights - Analysts have noted that the rationale for the partnership's announcement may be explained by executives from either company, potentially addressing the poor year-to-date performance of both firms [7]. - Goldman analyst James Quigley recently downgraded Novo's stock from "Buy" to "Hold," indicating a cautious outlook despite the new partnership [10].